Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIVEN phase 3 study of pexidartinib in symptomatic advanced PVNS or giant cell tumor of tendon sheath
2014-000148-14Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in tenosynovial giant cell tumor (TGCT) and giant cell tumor of tendon sheath (GCTTS) comparing Pexidartinib with Placebo (2 arms). Primary endpoint: RECIST 1.1 response rate at Week 25. Started Mar 2015; status: completed.
02
Drugs
pexidartinib
03
Conditions
tenosynovial giant cell tumor (TGCT)giant cell tumor of tendon sheath (GCTTS)
Beyond the preview
Go deeper on 2014-000148-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000148-14.